ScholarIQanswers from OpenAlex
Istituto Oncologico Veneto
InstitutionResearch output, impact & collaborations
Istituto Oncologico Veneto is a institution indexed in ScholarIQ from OpenAlex.
What is known about Istituto Oncologico Veneto?
ScholarIQrecord summary
Istituto Oncologico Veneto is a research organisation in Padua, IT. OpenAlex records 10,138 works and 636,089 citations for it. 1,537 researchers list it as their most recent affiliation.
How many works does Istituto Oncologico Veneto have?
ScholarIQindexed works
Istituto Oncologico Veneto has 10,138 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Istituto Oncologico Veneto have?
ScholarIQcitation count
Istituto Oncologico Veneto has 636,089 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Istituto Oncologico Veneto?
ScholarIQresearcher count
Istituto Oncologico Veneto has 1,537 researchers in the ScholarIQ index.
What is the average h-index at Istituto Oncologico Veneto?
ScholarIQavg h-index
Istituto Oncologico Veneto has an average h-index of 81.5 in OpenAlex.
What is the ROR of Istituto Oncologico Veneto?
ScholarIQror
The ROR for Istituto Oncologico Veneto is on the source record.
What is the OpenAlex record for Istituto Oncologico Veneto?
ScholarIQopenalex
The OpenAlex for Istituto Oncologico Veneto is on the source record.
Who are the most-cited researchers behind Istituto Oncologico Veneto?
ScholarIQtop researchers by citations
What are the most-cited papers on Istituto Oncologico Veneto?
ScholarIQmost cited works
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman, Ray McDermott, Joseph L. Leach, Sara Lonardi, Heinz‐Josef Lenz, Michael A. Morse, Jayesh Desai, Andrew Hill, Michael D. Axelson, Rebecca A. Moss, Monica V. Goldberg, Z. Alexander Cao, Jean-Marie Ledeine, Gregory A. Maglinte, Scott Kopetz, Thierry André
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu, Richard S. Finn, Julien Edeline, Stéphane Cattan, Sadahisa Ogasawara, Daniel H. Palmer, Chris Verslype, Vittorina Zagonel, Lætitia Fartoux, Arndt Vogel, Debashis Sarker, Gontran Verset, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Andrea L. Webber, Scot Ebbinghaus, Junshui Ma, Abby B. Siegel, Ann‐Lii Cheng, Masatoshi Kudo, Angela Alistar, Jamil Asselah, Jean‐Frédéric Blanc, Ivan Borbath, Timothy Lewis Cannon, Ki Y. Chung, Allen Lee Cohn, David Cosgrove, Nevena Damjanov, Mukul Gupta, Yoshivasu Karino, Mark Karwal, Andreas Kaubisch, Robin Kate Kelley, Jena-Luc Van Laethem, Timothy Larson, James Lee, Daneng Li, Atisha Manhas, Gulam A. Manji, Kazushi Numata, Benjamin M. Parsons, Andrew Scott Paulson, Carmine Pinto, Robert A. Ramirez, Suresh Ratnam, Magnus Rizell, Olivier Rosmorduc, Yvonne H. Sada, Yutaka Sasaki, Per Stål, Simone I. Strasser, Joerg Trojan, Gina M. Vaccaro, Hans Van Vlierberghe, Alan Weiss, Karl-Heinz Weiss, Tatsuya Yamashita
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
Michael J. Overman, Sara Lonardi, Ka Yeung Mark Wong, Heinz‐Josef Lenz, Fabio Gelsomino, Massimo Aglietta, Michael A. Morse, Eric Van Cutsem, Ray McDermott, Andrew Hill, Michael B. Sawyer, Alain Hendlisz, Bart Neyns, Magali Svrcek, Rebecca A. Moss, Jean-Marie Ledeine, Z. Alexander Cao, Shital Kamble, Scott Kopetz, Thierry André
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
Scott Kopetz, Axel Grothey, Rona Yaeger, Eric Van Cutsem, Jayesh Desai, Takayuki Yoshino, Harpreet Wasan, Fortunato Ciardiello, Fotios Loupakis, Yong Sang Hong, Neeltje Steeghs, Tormod Kyrre Guren, Hendrik‐Tobias Arkenau, Pilar García‐Alfonso, Per Pfeiffer, Sergey Orlov, Sara Lonardi, Elena Élez, Tae-Won Kim, Jan H.M. Schellens, Christina Guo, Asha Krishnan, Jeroen Dekervel, Van K. Morris, Aitana Calvo Ferrandiz, Line Schmidt Tarpgaard, Michael Braun, Ashwin Gollerkeri, Christopher Hunt Keir, Kati Maharry, Michael D. Pickard, Janna Christy‐Bittel, Lisa Anderson, Victor Sandor, Josep Tabernero
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
Chiara Cremolini, Fotios Loupakis, Carlotta Antoniotti, Cristiana Lupi, Elisa Sensi, Sara Lonardi, Silvia Mezi, Gianluca Tomasello, Monica Ronzoni, Alberto Zaniboni, Giuseppe Tonini, Chiara Carlomagno, Giacomo Allegrini, Silvana Chiara, Mauro D’Amico, Cristina Granetto, Marina Elena Cazzaniga, Luca Boni, Gabriella Fontanini, Alfredo Falcone
How much of the research on Istituto Oncologico Veneto is open access?
ScholarIQopen access share
83%OPEN ACCESS